TABLE 3.
Demographic data—movement disorders
| PD | PSP | CBD | MSA | |
|---|---|---|---|---|
| Description of the population | ||||
| Sample size, n | 2 | 8 | 6 | 6 |
| Male, n/n tot (%) | 0/2 (0%) | 3/8 (37.5%) | 4/6 (66.7%) | 4/6 (66.7%) |
| Age at symptom onset (years), mean ± SD |
72.0 ± 14.1 n tot = 2 |
65.5 ± 9.4 n tot = 8 |
67.7 ± 7.8 n tot = 6 |
58.6 ± 11.8 n tot = 5 |
| Duration of disease (years), mean ± SD |
2.5 ± 3.5 n tot = 2 |
8.2 ± 4.7 n tot = 8 |
9.2 ± 6.0 n tot = 6 |
4.6 ± 1.1 n tot = 5 |
| Age at death (years), mean ± SD |
74.5 ± 10.6 n tot = 2 |
73.7 ± 8.7 n tot = 8 |
76.8 ± 4.4 n tot = 6 |
63.3 ± 11.1 n tot = 6 |
| Clinical data | ||||
| Memory disorders, n/n tot (%) | 0/2 (0%) | 4/8 (50.0%) | 6/6 (100.0%) | 1/5 (20.0%) |
| Phasic disorders, n/n tot (%) | 0/2 (0%) | 6/8 (75.0%) | 4/6 (66.7%) | 0/5 (0%) |
| Praxis disorders, n/n tot (%) | 0/2 (0%) | 6/8 (75.0%) | 5/6 (83.3%) | 2/5 (40.0%) |
| Executive disorders, n/n tot (%) | 0/2 (0%) | 7/8 (87.5%) | 5/6 (83.3%) | 1/5 (20.0%) |
| Anxio‐depressive disorders, n/n tot (%) | 1/2 (50.0%) | 1/8 (12.5%) | 3/6 (50.0%) | 3/5 (60.0%) |
| Behavioral disorders, n/n tot (%) | 1/2 (50.0%) | 2/8 (25.0%) | 4/6 (66.7%) | 0/5 (0%) |
| Hallucinations/delirium, n/n tot (%) | 1/2 (50.0%) | 0/8 (0%) | 0/6 (0%) | 0/5 (0%) |
| Extrapyramidal syndrome, n/n tot (%) | 1/2 (50.0%) | 6/8 (75.0%) | 3/6 (50.0%) | 4/5 (80.0%) |
| Central motor symptoms, n/n tot (%) | 1/2 (50.0%) | 3/8 (37.5%) | 0/6 (0%) | 1/5 (20.0%) |
| Visual disturbances, n/n tot (%) | 0/2 (0%) | 7/8 (87.5%) | 0/6 (0%) | 3/5 (60.0%) |
| Paraclinical data | ||||
| Biomarker CSF, n | – | 1 (A+T−) |
1 (A−T+) 1 (A−T−) |
1 (A−T−) |
| CT‐scan/MRI abnormalities, n/n tot (%) | – | 7/7 (100.0%) | 6/6 (100.0%) | 2/3 (66.7%) |
| Neuropsychological tests abnormalities, n/n tot (%) | – | 7/8 (87.5%) | 6/6 (100.0%) | 1/1 (100.0%) |
| PET‐scan abnormalities, n/n tot (%) | – | 7/8 (87.5%) | 5/5 (100.0%) | 1/1 (100.0%) |
| DAT‐scan abnormalities, n/n tot (%) | – | – | 1/1 (100.0%) | 2/2 (100.0%) |
| Neuropathological data | ||||
| Immediate macroscopic analysis | ||||
| Brain weight (kg), mean ± SD |
1.38 ± 0.17 n tot = 2 |
1.21 ± 0.18 n tot = 8 |
1.16 ± 0.18 n tot = 6 |
1.30 ± 0.22 n tot = 5 |
Note: For each subgroup, the total number of headcount (n tot) is specified in case of missing data. Cerebrospinal fluid biomarkers profiles: biomarkers of Aβ plaques (labeled “A”) are low CSF Aβ42 or Aβ42/Aβ40 ratio; biomarkers of fibrillar Tau (labeled “T”) are elevated CSF phosphorylated tau (p‐Tau). Binarizing each of the two biomarker groups into normal/abnormal (−/+) results in four possible biomarker profiles: A+T+, A−T+, A+T−, A−T− [20].
Abbreviations: CBD, cortico basal degeneration; CSF, cerebro spinal fluid; CT, computed tomography; IHC, immunohistochemistry. MRI, magnetic resonance imaging; MSA, multiple system atrophy; PD, Parkinson's disease; PET, positron emission tomography; PSP, progressive supranuclear palsy.